No abstract available.
Lupus Erythematosus, Systemic* ; Pregnancy*

No abstract available.
Lupus Erythematosus, Systemic*

Study on 99 patients with systemic lupus erythematosus (SLE) who were diagnosed and treated at Dermatology hospital, and all patients had surveyed genotype of FC gamma RIIA. The control group consisted of 93 voluntary blood donors who were surveyed genotype of FCRIIA. Genotype of FCRIIA was defined by PCR-SSP method. Results: 4 PCR reactions were used to determine genotype of FCRIIA. The frequency of R/R131, R/H131 and H/H131 in 99 patients occurred in 15 (15.1%), 74 (74.1%) and 10 (10.1%), respectively and in 93 control persons were 11 (11.8%), 50 (53.8%) and 32 (34.4%), respectively. The distribution of frequency of 3 genotype between 2 groups was different with 2 = 16.16 and p<0.01. Genotype of FCRIIA could be the risk factors for the appearance of SLE in Vietnamese people.
Lupus Erythematosus, Systemic ; Diagnosis

No abstract available.
Lupus Erythematosus, Systemic*

No abstract available.
Endocarditis* ; Lupus Erythematosus, Systemic*

Background: system lupus erythematosus (SLE) is an autoimmune disease, characterized by a variety of antibodies generated against the body itself, causing damage in all organs: skin, mucous membranes, joint-skeletal-muscle, heart, kidneys, lungs, nervous, mental, blood and lymph,... The disease progresses in waves, more and more serious and lead to death. Objectives: to study on characteristics of patients with the end stage SLE and to evaluate results of some tests in these patients. Subjectives and Method: a retrospective and cross sectional study was carried out on forty two end stage SLE patients at Department of Allergology and Clinical Immunology of Bach Mai hospital were studied between 1998 and 2004. Results: the majority of SLE patients were female (90.48%) and in group of 16-39 years old. Number of female patients was 14 times more than male patients. All 42 patients decreased peripheral blood cell amount: reducing both red and white blood cells (71.43%), reducing both three type (11.90%). 21/32 cases with severe hemoglobin reduction (65.53%). 38/42 cases of medium and severe neutropenia (90.48%). 33/42 cases with end-stage renal failure (78.57%). 13 cases of low blood Na+, 9 cases of increased blood K+. 30 cases with positive proteinuria (90.91%). 17/20 cases with pericardial effusion (85.00%). 35/42 cases with lung lesion images on ultrasound and x-rays (83.33%). 9 cases (30.00%) with increased AST and ALT above 100 U/l. 5 cases (16.67%) with meningitis. Conclusions: dramatic decrease in blood cell count, particularly in white blood cells. Most patients had renal failure at stage III, mainly with high blood potassium, and high protein and red blood cells in urine. Others included pericarditis, pneumonia, liver and neurological disorders.
Lupus Erythematosus ; Systemic/epidemiology ;

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems that is characterized by the occurrence of antibodies directed against antigens. In this study, we mention 2 matters as following: (1) General conclusion on clinical manifestation and subjects of SLE patients treated in the Allergy-Immune Department of Bachmai Hospital from 1996-2000. (2) The role of immune tests for SLE patients, especially Combs and erythrocytic existing tests for SLE patients with anemia. We study 438 patients with clinical manifestation and subsets, researched document of 418 patients and carried out Combs and erythrocytic existing tests in 20 SLE patients treated in Allergy-Immune Department of Bachmai hospital. SLE are found mainly in woman (93.6%), concentrating in the child-bearing age. Hematological disorders (83.8%), "butterfly" rashes (81.9%), arthritis (81.2%) and renal damages (78.5%) are common symptoms. Positive nuclear antibodies occur in 76.3% of patients, antibodies to DNA in 60.5% and LE cell in 40.9%. The rater of 50% of patients with positive Combs test and 55% of patients with damaged erythocytic membranes have played an important role in demonstrating the hemolytic mechanism in SLE patients.
Lupus Erythematosus, Systemic ; Therapy

No abstract available.
Antibodies, Antinuclear* ; Scleroderma, Systemic*

No Abstract Available.
Lupus Erythematosus, Systemic*

No abstract available.
Lupus Erythematosus, Systemic*